Rheumatology
Journal Abbreviation: RHEUMATOLOGY
ISSN: 1462-0324
eISSN: 1462-0332
Publisher: Oxford University Press
Publications (93)
Checkpoint inhibitor-induced eosinophilic fasciitis following high eosinophilia associated with complete response (2019)
Toussaint F, Hammon M, Erdmann M, Moreira A, Kirchberger MC, Schuler G, Schett G, Heinzerling L
Journal article
Analyses of association of psoriatic arthritis and psoriasis vulgaris with functional NCF1 variants (2019)
Löhr S, Ekici AB, Uebe S, Büttner C, Köhm M, Behrens F, Böhm B, et al.
Journal article
EFFECTS OF BASELINE PREDNISONE DOSE ON REMISSION AND DISEASE FLARE IN PATIENTS WITH GIANT CELL ARTERITIS TREATED WITH TOCILIZUMAB IN THE GIACTA TRIAL (2019)
Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, Brouwer E, et al.
Conference contribution
Secukinumab provides sustained improvements in the signs and symptoms in psoriatic arthritis: final 5-year efficacy and safety results from the FUTURE 1 Phase 3 trial (2019)
Tahir H, Mease PJ, Kavanaugh A, Reimold A, Rech J, Hall S, Geusens P, et al.
Conference contribution
GENETIC EVIDENCE OF EOSINOPHIL NUMBER UNDERPINNING PR3-AAV AND PLAUSIBLE HOST GENETIC PREDISPOSITION TO MICROBIAL DRIVERS OF DISEASE (2019)
Wong L, Mescia F, Alberici F, Ball MJ, Baslund B, Brenchley P, Bruchfeld A, et al.
Conference contribution
EFFECTS OF BASELINE PREDNISONE DOSE ON REMISSION AND DISEASE FLARE IN PATIENTS WITH GIANT CELL ARTERITIS TREATED WITH TOCILIZUMAB IN A PHASE 3 RANDOMIZED CONTROLLED TRIAL (2019)
Stone J, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, Brouwer E, et al.
Conference contribution
SECUKINUMAB PROVIDES RAPID AND SUSTAINED RESOLUTION OF ENTHESITIS IN PSORIATIC ARTHRITIS PATIENTS: POOLED ANALYSIS OF TWO PHASE 3 STUDIES, FUTURE 2 AND FUTURE 3 (2019)
Coates LC, Mcgonagle D, Schett G, Mease PJ, Quebe-Fehling E, Asquith DL, Rasouliyan L, et al.
Conference contribution
IMPACT OF SECUKINUMAB TREATMENT ON PSORIATIC ARTHRITIS PATIENTS WITH OR WITHOUT ENTHESITIS AT BASELINE: POOLED DATA FROM FUTURE 2 AND FUTURE 3 PHASE 3 STUDIES (2019)
Mcinnes IB, Wallman JK, Schett G, Quebe-Fehling E, Rasouliyan L, Pricop L, Fasth AE, Gaillez C
Conference contribution
ACUTE PHASE REACTANT LEVELS AND PREDNISONE DOSES AT DISEASE FLARE IN PATIENTS WITH GIANT CELL ARTERITIS: PROSPECTIVE DATA FROM THE GIACTA TRIAL (2019)
Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, Brouwer E, et al.
Conference contribution
LONG-TERM (156-WEEK) IMPROVEMENTS IN DACTYLITIS AND ENTHESITIS WITH APREMILAST INPSORIATIC ARTHRITIS SUBJECTS: ANALYSIS OF A LARGE, POOLED PALACE 1-3 DATABASE (2018)
Gladman DD, Kavanaugh A, Gomez-Reino JJ, Wollenhaupt J, Cutolo M, Schett G, Lespessailles E, et al.
Conference contribution